麻豆女优

Publications

Alanazi Ibrahim M, Alzahrani Abdullah R, Alsaad Mohammad A, Moqeem Abdulaziz L, Hamdi Abdulmohsen M, Taher Mohiuddin M, Watson David G,

Saudi Pharmaceutical Journal Vol 32 (2024)

, Meek Dominic R M, Tate Rothwelle, Brady Adrian, MacMillan Sandy, ,

The Bone & Joint Journal Vol 106-B, pp. 51-58 (2024)

Meek Dominic, Jenkinson Mark, MacMillan Sandy, Tate Rothwelle, ,

International Hip Society conference, pp. 31-31 (2023)

Alanazi Ibrahim M, Alzahrani Abdullah R, Zughaibi Torki A, Al-Asmari Ahmed I, Tabrez Shams, , Watson David,

Metabolites Vol 13 (2023)

, Meek Dominic, MacMillan Sandy, Tate Rothwelle, ,

Heart Vol 109, pp. A4.1-A4 (2023)

Olatunji Zainab O, MacMillan Sandy, Cameron-Ruiz Miren, , , , Tate Rothwelle, MacQuaide Niall,

Heart Vol 109 (2023)

Professional Activities

Participant

2019

Advisor

17/6/2017

Projects

Currie, Susan (Principal Investigator) Grant, Mary (Co-investigator) Tate, Rothwelle (Co-investigator)

01-Jan-2019 - 31-Jan-2021

Grant, Mary (Principal Investigator)

01-Jan-2015 - 30-Jan-2019

Zagnoni, Michele (Principal Investigator) Grant, Mary (Co-investigator) Claasen, Myndert (Research Co-investigator)

01-Jan-2014 - 15-Jan-2020

Grant, Mary (Principal Investigator) Patwardhan, Siddharth (Principal Investigator) Urquhart, Andrew (Principal Investigator)

Although nanoparticles are extensively used in a wide range of commercial applications, the understanding of their toxicity has started to emerge only recently and confusion regarding their safe use is widespread. In this project, we aim to assess the toxicity of newly-invented nanoparticles which have applications in biomedical materials such as drug delivery. Consequences of exposure to the nanoparticles will be assessed (using appropriate ISO standard protocols) by effects on viability, proliferation and cytokine release. One outcome of this project will be known toxicity and drug delivering ability of new nanoparticles.

05-Jan-2011 - 01-Jan-2012

Grant, Mary (Principal Investigator)

01-Jan-2011 - 30-Jan-2012

Grant, Mary (Principal Investigator)

The toxicty of novel candidate pharmaceuicals is usually tested in animals. Cultured liver cells (hepatocytes) are being developed for in vitro testing of toxicity in order to reduce and replace the use of animals. Instability of their functions in culture is limiting progress towards this aim. This project investigates the potential of a new culture matrix (Orla 3-D Cell Carrier glass matrix) developed by Orla Protein Technologies to maintain functional hepatocytes in a 3-dimensional configuration.

01-Jan-2011 - 30-Jan-2011